Revolution Medicines Inc. | Mid-cap | Healthcare
$37.01
1.45%
| Revolution Medicines Stock Comparison:
Revolution Medicines vs VertexRevolution Medicines vs RegeneronRevolution Medicines vs BridgeBio PharmaRevolution Medicines vs MadrigalRevolution Medicines vs Blueprint MedicinesRevolution Medicines vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Operating Income -240.8M
Net Income -213.4M
EPS (Diluted) $-1.13

Balance Sheet Metrics

Total Assets 2.4B
Total Liabilities 287.2M
Shareholders Equity 2.1B
Debt to Equity 0.14

Cash Flow Metrics

Operating Cash Flow -190.2M
Free Cash Flow -197.7M

Revenue & Profitability Trend

Revolution Medicines Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i011.6M35.4M29.4M43.0M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i592.2M423.1M253.1M186.9M132.3M
Selling, General & Administrative i97.3M75.6M40.6M30.4M21.4M
Other Operating Expenses i-----
Total Operating Expenses i689.5M498.8M293.7M217.4M153.7M
Operating Income i-689.5M-487.2M-258.3M-188.0M-110.7M
Operating Margin % i0.0%-4,207.1%-730.0%-639.7%-257.5%
Non-Operating Items
Interest Income i86.9M47.5M9.2M929.0K2.2M
Interest Expense i-303.0K012.0K71.0K
Other Non-Operating Income1.8M115.0K---
Pre-tax Income i-600.8M-439.9M-249.1M-187.1M-108.5M
Income Tax i-753.0K-3.5M-420.0K0-371.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-600.1M-436.4M-248.7M-187.1M-108.2M
Net Margin % i0.0%-3,768.3%-703.0%-636.6%-251.6%
Key Metrics
EBITDA i-682.0M-430.3M-239.5M-179.7M-101.9M
EPS (Basic) i$-3.58$-3.86$-3.08$-2.57$-2.01
EPS (Diluted) i$-3.58$-3.86$-3.08$-2.57$-2.01
Basic Shares Outstanding i167737672113149869806265257280607954874119
Diluted Shares Outstanding i167737672113149869806265257280607954874119

Income Statement Trend

Revolution Medicines Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i543.1M696.1M161.4M108.5M104.3M
Short-term Investments i1.7B1.2B483.5M468.6M336.5M
Accounts Receivable i01.3M4.7M5.9M6.4M
Inventory i-----
Other Current Assets38.3M25.1M10.6M6.8M7.0M
Total Current Assets i2.3B1.9B660.2M589.8M454.1M
Non-Current Assets
Property, Plant & Equipment i142.7M98.7M72.2M72.4M37.4M
Goodwill i85.9M87.0M88.0M89.1M90.2M
Intangible Assets i56.7M57.7M58.8M59.9M60.9M
Long-term Investments-----
Other Non-Current Assets17.6M10.1M4.6M2.5M1.4M
Total Non-Current Assets i230.7M182.4M151.7M148.2M113.3M
Total Assets i2.6B2.1B811.9M738.0M567.4M
Liabilities
Current Liabilities
Accounts Payable i54.4M61.8M21.3M14.1M12.6M
Short-term Debt i12.9M7.4M6.8M6.2M3.7M
Current Portion of Long-term Debt-----
Other Current Liabilities583.0K3.9M505.0K311.0K97.0K
Total Current Liabilities i163.9M143.9M62.0M60.4M47.2M
Non-Current Liabilities
Long-term Debt i123.0M80.6M57.4M60.4M29.0M
Deferred Tax Liabilities i2.4M3.1M7.0M7.4M7.4M
Other Non-Current Liabilities670.0K1.5M301.0K634.0K632.0K
Total Non-Current Liabilities i129.2M91.7M64.8M75.1M45.5M
Total Liabilities i293.1M235.5M126.7M135.4M92.7M
Equity
Common Stock i18.0K16.0K9.0K8.0K7.0K
Retained Earnings i-1.7B-1.1B-701.3M-452.6M-265.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i2.3B1.8B685.2M602.6M474.7M
Key Metrics
Total Debt i135.8M87.9M64.2M66.6M32.7M
Working Capital i2.2B1.7B598.2M529.4M406.9M

Balance Sheet Composition

Revolution Medicines Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-600.1M-436.4M-248.7M-187.1M-108.2M
Depreciation & Amortization i11.8M9.3M9.7M7.3M6.5M
Stock-Based Compensation i79.2M61.8M31.2M20.7M8.9M
Working Capital Changes i-11.9M24.7M-11.2M-194.0K-11.2M
Operating Cash Flow i-521.0M-340.6M-219.1M-159.2M-104.0M
Investing Activities
Capital Expenditures i-10.3M-7.7M-10.8M-6.5M-2.9M
Acquisitions i----0
Investment Purchases i-2.1B-1.1B-612.8M-671.3M-544.1M
Investment Sales i1.6B724.0M599.5M535.7M312.8M
Investing Cash Flow i-554.4M-342.6M-24.1M-142.1M-234.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i846.6M1.2B298.1M290.8M420.1M
Free Cash Flow i-567.7M-358.3M-235.2M-153.7M-103.0M
Net Change in Cash i-228.7M539.4M54.9M-10.5M81.9M

Cash Flow Trend

Revolution Medicines Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -10.10
Forward P/E -9.02
Price to Book 3.66
PEG Ratio -0.16

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -46.61%
Return on Assets -26.47%

Financial Health

Current Ratio 11.79
Debt to Equity 7.12
Beta 1.16

Per Share Data

EPS (TTM) $-4.52
Book Value per Share $9.98
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
rvmd6.8B-10.103.66-46.61%0.00%7.12
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
BridgeBio Pharma 9.6B-17.12-5.2836.76%98.25%-1.04
Madrigal 8.5B-17.6712.12-36.30%-54.68%17.81
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.